On Friday, Shares of Twenty-First Century Fox, Inc. (NASDAQ:FOXA), lost -0.33% to $32.91.
The Board of Twenty-First Century Fox, declared a series of senior administration changes, which will take effect July 1, 2015.
Rupert Murdoch, the Company’s founder and Chairman and CEO, together with Lachlan Murdoch, presently Co-Chairman, will become Executive Co-Chairmen.
Chase Carey, the Company’s Deputy Chairman, President and COO since 2009, will become the Executive Vice Chairman and serve in that role through June 30, 2016.
James Murdoch, presently Co-Chief Operating Officer, will become Chief Executive Officer.
In conjunction with these changes, the Company’s corporate functions, and its global television and film operations will now jointly report to Lachlan and James Murdoch.
Rupert Murdoch said: “It has always been our priority to ensure stable, long term leadership for the Company, and these appointments achieve that aim. Lachlan and James are each talented and accomplished executives and together, we, as shareholders and partners, will strive to take our company to new levels of growth and opportunity at a time of dynamic change in our industry.”
He added: “I can’t thank Chase Carey enough for his friendship, counsel and leadership over the past decades. He will be actively engaged in supporting Lachlan and James as they step in to their new roles.”
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming, Television, Filmed Entertainment, and Direct Broadcast Satellite Television segments.
Shares of Merck & Co. Inc. (NYSE:MRK), declined -0.94% to $58.04, during its last trading session.
A unit of Merck & Co Inc has agreed to pay $5.9 million to resolve claims that it fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities declared on last Wednesday, according to Reuters.
Manhattan U.S. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck attained in 2011, promoted its drug AzaSite to healthcare providers for uses the Food and Drug Administration had not approved as safe and effective. Reuters Reports.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, Molycorp, Inc. (NYSE:MCP), ended its last trade with -4.95% loss, and closed at $0.43.
Molycorp Inc. said it plans to take advantage of a 30-day grace period for a $3.36 million semiannual interest payment due Monday, during which the struggling rare-earths elements miner and processor plans to evaluate various options for restructuring its debt load, WSJ Reports.
Molycorp, Inc. produces and sells rare earths and rare metal materials in the United States and internationally. The company’s Resources segment extracts rare earth minerals, counting light rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, and neodymium-praseodymium; heavy rare earth concentrates, which comprise samarium, europium, gadolinium, terbium, dysprosium, and others; and SorbX and PhosFIX, a line of rare earth-based water treatment products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
